A literature search revealed there is no international agreement on how to characterize or classify endometriosis.
The search in the Journal of Minimally Invasive Gynecology also concluded that most classification/staging systems show little to no correlation with patient outcomes.
The search, which was limited to PubMed and MEDLINE, and English language studies published from inception in 1966 to August 2020, comprised 70 studies that either described a classification, staging, or reporting system in endometriosis (n = 24) or evaluated 1 (n = 46). A total of 22 endometriosis classification-staging-reporting systems were assessed.1
The studies highlighted a discrepancy between the intended and the evaluated purpose. There is also a general lack of validation data confirming a correlation between pain symptoms or quality of life to any of the current systems.
A few studies, though, confirm the value of the Enzian system for surgical description of deep endometriosis. Also, the endometriosis fertility index (EFI) has been validated for its intended purpose of predicting the probability of natural conception after surgery. However, the EFI system needs further evaluation of the importance of the different parameters and whether to include the completeness of surgical treatment.
The revised American Society for Reproductive Medicine (rASRM) system has also been evaluated, but often with negative conclusions.
Apart from rASRM, Enzian, and EFI, only 2 other classification systems have been evaluated for their intended purpose: the ultrasound-based endometriosis staging system (UBESS) and the disease extent, complaints, objectives (ECO).
“This overview of existing systems is a first step in working towards a universally accepted endometriosis classification,” wrote the authors, who acknowledged that endometriosis is a challenging disease to classify because it has different phenotypes and presentations for the type of lesions and their location. The disease also has various symptoms without a clear connection to phenotype or presentation.
Furthermore, the natural progression of endometriosis is unknown.
Despite these roadblocks, there appears to be a need for a validated classification or descriptive system for endometriosis to support further progress in defining subgroups. More significant, though, is that such a system could guide therapeutic options for women with pain and/or infertility.
System conformity would also assist endometriosis research by unifying patient subgroups and enhance the development of prognostic and predictive tools.
“Classification and staging systems are widely used in medicine and have been shown to be valuable in guiding clinical management,” wrote the authors, including the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging systems for cancer, which was developed in the early 1950s to guide clinical classification of cancer cases by anatomical extent.
The TNM system, which is revised every 6 to 8 years, is now in its eighth edition and includes a summary staging or classification linked to prognosis and used for treatment planning.
The TNM system has also been increasingly complemented by molecular marker data that more accurately stratifies risk in patients and guides appropriate treatment options.
The longevity and update systems applied to TNM staging, plus the additional molecular subtype identification, are probably salient guides for the design of future endometriosis classification and staging systems that correlate with relevant patient outcomes, according to the authors.
Meanwhile, the goal and purpose of published classification, staging or reporting systems for endometriosis are often ignored when assessing classification or staging systems, thus limiting the value of the evaluation studies and of the systems in general, according to the authors.
Reference
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More